跳至主要内容
临床试验/IRCT20201003048904N2
IRCT20201003048904N2已完成未知

: Evaluation of the effect of spironolactone and DDP4 inhibitors on treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19)

Boushehr University of Medical Sciences0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 no limit(—)
性别
All

入选标准

  • admitted patients in Bushehr's Shohadaye_Khalije_Fars hospital due to COVID19 diagnosis confirmed by Rt-PCR
  • age equal or more than 20
  • Male and female OPD patients with confirmed or probable SARS-CoV-2 infection according to WHO and CDC definitions referred to Motahari Clinic.

排除标准

  • positive history of spironolactone or DPP4 inhibitor consumption
  • contraindications for drug intervention consumption (Plasma Acid/base, Electrolyte or Glucose abnormalities)
  • hypersensitivity to drugs
  • patient dissatisfaction
  • intubation and mechanical ventilation at admission onset

研究者

发起方
Boushehr University of Medical Sciences

相似试验

combination therapy trial in COVID-19 patients | 临床试验